SCHEMBL6488495

SCHEMBL6488495

Cc1ccccc1-c1ccc(C(=O)N[C@H]2CN3CCC2CC3C)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 2/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRNA7 P36544 5/20 0.42
HTR3A P46098 1/20 0.42
SLC9A1 P19634 1/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496106 0.90 CHRNA7 (0.44) ALDH1A1POLBCHRNA7HTR3ANPC1
SCHEMBL6502115 0.89 RAB9A (0.52) ALDH1A1HPGDLMNAMAPTMAPK1
SCHEMBL6632514 0.89 RAB9A (0.52) ALDH1A1HPGDLMNAMAPTMAPK1
SCHEMBL6490697 0.89 CHRNA7 (0.43) ALDH1A1POLBCHRNA7HTR3ASLC9A1
SCHEMBL6492376 0.89 RAB9A (0.48) ALDH1A1HPGDKDM4EPOLBMAPT
SCHEMBL6487870 0.88 CHRNA7 (0.53) ALDH1A1HPGDKDM4EPOLBMAPT
SCHEMBL6497753 0.87 ALDH1A1 (0.52) ALDH1A1KDM4EPOLBMAPTMEN1
SCHEMBL6491301 0.87 SMN1; SMN2 (0.44) ALDH1A1HPGDKDM4EPOLBLMNA
SCHEMBL7061100 0.84 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EPOLBCHRNA7
SCHEMBL6487899 0.84 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885HPGD 706/4885KDM4E 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.